Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data from a Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the IL-17 receptor, being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013. 

"The brodalumab data being presented at EULAR demonstrate a positive benefit-risk profile for patients with psoriatic arthritis," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We are encouraged by these data as we continue to explore brodalumab for its potential to treat patients with inflammatory disease including psoriatic arthritis."

Based on the Phase 2 results, the companies intend to advance brodalumab into Phase 3 clinical studies for the treatment of psoriatic arthritis in 2014.

"This brodalumab data marks a positive step forward for patients with psoriatic arthritis," said Dr. Bahija Jallal, executive vice president, MedImmune.  "We look forward to working with Amgen to further evaluate this novel therapy in psoriatic arthritis and potentially other chronic immune-mediated diseases."

ABSTRACT OF INTEREST:

Brodalumab Abstract at EULAR:

  • Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis
    Abstract No. OP0103, Oral Presentation, Thursday, June 13, 10:20 a.m. CET, N117

Abstracts are currently available on the EULAR website at www.eular.org.

About Brodal
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 North Shore ... York City, partnered with GI Energy, one of the nation’s ... a $13 million upgrade of its 43-year-old CHP system. The ... and in an effort to extend the life of the ... generators and associated electrical and heat recovery equipment, while maintaining ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading provider ... today announced that it will hold an investor conference ... financial results for the first quarter of fiscal 2015 ... the current fiscal year. , The dial-in number for ... 2014, at 5 p.m. EDT (2 p.m. PDT) is ...
(Date:7/31/2014)... SAN DIEGO and SHENZHEN, China ... Genomics announced today the purchase of an ... genomics organization. BGI selected BioNano,s platform to enable comprehensive ... vastly improved assemblies for various organisms of interest, including ... BGI will partner together to develop new methods for ...
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5
... April 1, 2008 Cardium Therapeutics,(Amex: ... Therapies announced today that,InnerCool has entered into ... (Euromed), a leading distributor of cardiology,medical products. ... will have,exclusive marketing, sales and distribution rights ...
... April 1, 2008 Piedmont Heart Institute (PHI),expands ... cardiovascular,physician practice, Cardiology of Georgia, P.C. (COG), through ... 2008. With eight,locations including Buckhead, Canton, Fayetteville and ... under the Piedmont Heart Institute and an,important addition ...
... 1, 2008 ,Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... Loar has been appointed Chief,Financial Officer. Mr. Loar will ... joins the company from Osteologix, where he has served,as ... proven track record as a chief financial officer, and ...
Cached Biology Technology:Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... Carroll,s Through the Looking Glass, collaborators from the ... improved a 35-year-old ecology model to better understand ... years. , The new model, called a mean ... Effect," an evolutionary hypothesis introduced by Lee Van ... must constantly increase their fitness (or ability to ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... interdisciplinary perspective. Presenters at the National Academy of Sciences, ... ways to identify, encourage, and support advances in climate ... other fields. In addition, U.S. Secretary ... Sackler Lecture beginning at 6 p.m. on March 31 ...
... Providing further understanding of the link between low birth ... deprived newborns are "programmed" to eat more because they ... that controls food intake, according to an article published ... The study by a team of researchers at Los ...
... of people commit suicide worldwide each year, researchers and ... person,s likelihood of thinking about or trying to commit ... Hospital del Mar Research Institute (IMIM) has participated, has ... suicides. "It is of key importance to identify suicidal ...
Cached Biology News:Study provides explanation for connection between low birth weight and obesity later in life 2First international index developed to predict suicidal behavior 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Biology Products: